date:Nov 29, 2018
an agreement with Novartis for the buyout of Novartis 36.5 percent stake in their Consumer Healthcare Joint Venture for US$13 billion.
Long-established Horlicks, which is sold through GSKs Indian subsidiary, has a solid track record. Speaking during a press conference call held earlier this year, GSK CEO Emma Walmsley, stressed that India remains a priority market for GSK, a key location for growth opportunities. Walmsley also described Horlicks as absolutely extraordinary brand with more than